148 results on '"Potvin, Diane"'
Search Results
2. Efficacy and safety of LAU-7b in a Phase 2 trial in adults with cystic fibrosis
3. Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors
4. Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors
5. First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)
6. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma
7. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm
8. Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors
9. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors
10. Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial
11. Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors
12. Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.
13. Characteristics and relationship between hyperphagia, anxiety, behavioral challenges and caregiver burden in Prader-Willi syndrome
14. Metabolic effects of a growth hormone-releasing factor in patients with HIV
15. Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects
16. Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers
17. Comparison of Different Methods to Evaluate Population Dose–Response and Relative Potency: Importance of Interoccasion Variability
18. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction
19. Truncated Area Under the Curve as a Measure of Relative Extent of Bioavailability: Evaluation Using Experimental Data and Monte Carlo Simulations
20. Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data
21. A Parametric Confidence Interval for a Moment-Based Scaled Criterion for Individual Bioequivalence
22. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
23. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin
24. A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.
25. Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes
26. Suggestions for Streamlining and Optimizing Clinical End‐Point Bioequivalence Studies for US Abbreviated New Drug Application Submissions
27. Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).
28. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial
29. Enabling factors related to prosthetic use by people with transtibial and transfemoral amputation
30. P2.06-001 A Study of MGCD516, a Receptor Tyrosine Kinase (RTK) Inhibitor, in Molecularly Selected Patients with NSCLC or Other Advanced Solid Tumors
31. P2.06-017 Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET
32. P2.06-014 Phase 2 Study of Glesatinib or Sitravatinib with Nivolumab in Non-Small Cell Lung Cancer (NSCLC) after Checkpoint Inhibitor Therapy
33. P2.06-008 Phase 1/2 Study of Mocetinostat and Durvalumab (MEDI4736) in Patients with Advanced Solid Tumors and Non Small Cell Lung Cancer (NSCLC)
34. Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
35. Optimal adaptive sequential designs for crossover bioequivalence studies
36. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.
37. Suggestions for Streamlining and Optimizing Clinical End‐Point Bioequivalence Studies for US Abbreviated New Drug Application Submissions.
38. Optimal adaptive sequential designs for crossover bioequivalence studies.
39. Additional results for ‘Sequential design approaches for bioequivalence studies with crossover designs’
40. Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension
41. Sequential design approaches for bioequivalence studies with crossover designs
42. Effects of Ciprofloxacin on the Stereoselective Disposition of Mexiletine in Man
43. Carry-over in cross-over trials in bioequivalence: theoretical concerns and empirical evidence
44. CARRY-OVER EFFECTS IN BIOEQUIVALENCE STUDIES
45. Numerical methods for the evaluation of individual bioequivalence criteria
46. Predisposing Factors Related to Prosthetic Use by People with a Transtibial and Transfemoral Amputation
47. Effects of a Neutral Answer Choice on the Reliability and Validity of Attitude and Opinion Items
48. Factors Associated with Length of Survival among 1081 Terminally Ill Cancer Patients
49. Prognostic significance of cathepsin‐D expression in node‐positive breast carcinoma: An immunohistochemical study
50. Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.